PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT05626322
- Locations
- 🇺🇸
LSU Health Baton Rouge North Clinic, Baton Rouge, Louisiana, United States
🇺🇸Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
🇺🇸Thompson Cancer Survival Center, Knoxville, Tennessee, United States
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Conditions
- Interventions
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1116
- Registration Number
- NCT05623020
- Locations
- 🇮🇹
ASL PESCARA-Presidio Ospedaliero Pescara, Pescara, Italy
🇮🇹AOU Policlinico Umberto I, Roma, Italy
🇦🇺Pindara Private Hospital, Benowa, Queensland, Australia
A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05621239
- Locations
- 🇮🇩
Pfizer, Jakarta, Indonesia
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT05611801
- Locations
- 🇹🇷
Gazi University Health Research and Application Center Gazi Hospital, Ankara, Turkey
🇹🇷Erciyes Universitesi Tıp Fakultesi Hastaneleri, Kayseri, Turkey
🇹🇷Ondokuz Mayıs Universitesi, Samsun, Turkey
Ngenla Subcutaneous Injection Special Investigation
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05602766
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
Post Marketing Surveillance(PMS) Study of Lorviqua in Korea
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT05599412
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT05597085
- Locations
- 🇮🇳
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, Delhi, India
🇮🇳Fortis Memorial Research Institute, Gurugram, Haryana, India
🇮🇳Tata Medical Center, Kolkata, WEST Bengal, India
A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 150
- Registration Number
- NCT05584644
- Locations
- 🇮🇳
HCG Cancer Centre, Ahmedabad, Gujarat, India, India
🇮🇳Bhagwan Mahaveer Cancer Hospital and Research Centre, Bajaj Nagar, Jaipur, Rajasthan, India, India
🇮🇳Hemato Oncology Clinic Ahmedabad Private Limited, Rajpath Club Lane ,Gujarat, India, Ahmedabad, India
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT05583526
- Locations
- 🇨🇦
Whitby Health Centre Dermatology trials, Whitby, Ontario, Canada
🇨🇦Whitby Health Centre, Whitby, Ontario, Canada
🇨🇦Centre de Recherche Dermatologique du Quebec metropolitain, Quebec, Canada
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 94
- Registration Number
- NCT05580003
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇧🇪Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium